VERZENIO® is a prescription medicine used in combination with endocrine therapy for the adjuvant treatment of adult patients with HR-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence. It is also used in combination with an aromatase inhibitor as initial endocrine-based therapy for HR-positive, HER2-negative advanced or metastatic breast cancer. Additionally, it is used in combination with fulvestrant for patients with HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy, and as monotherapy for patients with HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression after endocrine therapy and prior chemotherapy.